MSManaphat Suksai

Manaphat Suksai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manaphat Suksai has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pre‐eclampsia screening and prevention: Implementing FIGO guidelines in a Thai population

    by Intouch Sophark, Manaphat Suksai, Alan Geater, Thitima Suntharasaj, Chitkasaem Suwanrath, Ninlapa Pruksanusak

    Objective: To evaluate the real‐world implementation, screening performance, aspirin uptake, and safety of a FIGO (the International Federation of Gynecology & Obstetrics)‐based first‐trimester pre‐eclampsia screening and prevention program. Methods: This retrospective cohort study included women initiating antenatal care before 14 weeks of gestation at a tertiary referral center in southern Thailand from 2021 to 2024. Screening incorporated maternal factors, mean arterial pressure, and uterine artery pulsatility index. Women with a calculated risk of 1:100 or greater were classified as being at high risk and offered aspirin 162 mg nightly. Outcomes included screening coverage, detection rates, aspirin uptake, pregnancy outcomes, and bleeding complications. Results: Among 1713 pregnancies, 71 developed pre‐eclampsia (4.1%), including 49 with severe features. Overall, 1106 women were screened (64.6%), but coverage reached 93.6% by the end of implementation. The screen‐positive rate was 11.3%. Detection rates were 61.7% for overall pre‐eclampsia, 69.6% for delivery before 37 weeks of gestation, 87.5% for delivery before 34 weeks of gestation, and 100% for delivery before 32 weeks of gestation, with false‐positive rates of approximately 9%–11%. Aspirin uptake among screen‐positive women was 99.2%. Pre‐eclampsia was associated with higher rates of cesarean delivery, preterm birth, lower birth weight, and neonatal intensive care unit admission. No eclampsia, placental abruption, maternal intensive care unit admission, maternal death, stillbirth, or neonatal death occurred. After adjustment for potential confounders, aspirin was not associated with the risk of an estimated blood loss of 500 mL or more, and the risk of an estimated blood loss of 1000 mL or more did not differ significantly between groups. Conclusion: FIGO‐based first‐trimester screening was feasible in routine care, with increasing coverage as implementation matured, near‐universal aspirin uptake, and clinically useful detection of preterm pre‐eclampsia. Aspirin use was not significantly associated with severe bleeding.

  • Placental Assessment Using Microvascular Flow Imaging: Reference Ranges and Clinical Application

    by Manaphat Suksai, Alan Geater, Thitima Suntharasaj, Chitkasaem Suwanrath, Ninlapa Pruksanusak, Natthicha Chainarong

    Objectives: To establish gestational age‐specific reference ranges for the intraplacental vascular index measured using microvascularity‐flow ultrasound software (VI MV ) and to evaluate its variation by placental location, parity, and pregnancy outcome. Methods: This prospective study enrolled 354 singleton pregnancies, of which 243 (68.64%) uncomplicated cases were used to construct reference ranges. A residual bootstrap method with 500 iterations was applied to square‐root–transformed VI MV values, followed by back‐transformation to derive the 5th, 50th, and 95th percentiles with 95% confidence intervals. Group differences were assessed using quantile regression, and associations with Doppler parameters were examined. Results: VI MV increased significantly with advancing gestational age (linear coefficient 1.88, p = .007), following a curvilinear pattern with mild late‐gestation downturn (quadratic coefficient − 0.036, p = .011). Posterior placentas showed slightly higher early values, although this difference was not significant; from 31 weeks onward, anterior placentas demonstrated significantly higher VI MV (mean difference + 15.4, p = .010 at 31–35 weeks; +11.6, p = .003 at 36–40 weeks). Multiparous women showed a modestly higher fitted trajectory and a similar non‐significant trend toward higher birthweight, but parity was not independently associated with VI MV . Pregnancies complicated by maternal disease, hypertensive disorders, or small‐for‐gestational‐age neonates exhibited lower trajectories than uncomplicated pregnancies, although these differences were not statistically significant. VI MV was inversely associated with uterine and umbilical artery pulsatility indices and positively associated with umbilical vein time‐averaged mean velocity. Conclusions: Gestational age–specific VI MV reference ranges were established. VI MV may provide an adjunctive quantitative marker for assessing placental vascular adaptation and identifying pregnancies with altered placental perfusion.

  • Response: A risk scoring model for predicting adverse maternal outcomes in pregnancy with pre‐eclampsia

    by Manaphat Suksai, Alan Geater, Pawinee Amornchat, Chitkasaem Suwanrath

  • A risk scoring model for predicting adverse maternal outcomes in pregnancy with pre‐eclampsia

    by Manaphat Suksai, Alan Geater, Pawinee Amornchat, Chitkasaem Suwanrath

    Objective: Pre‐eclampsia can lead to mortality and morbidity. The aim of this study was to establish a multivariate model to predict the adverse maternal events associated with pre‐eclampsia in the Thai population and to provide the composite measure of adverse perinatal events. Methods: A retrospective study was conducted at the Songklanagarind Hospital between January 2011 and December 2020. Multivariable logistic regression analysis was used to identify clinical risk factors for adverse maternal outcomes in pregnancies complicated with pre‐eclampsia and to establish a predictive model. A nomogram was generated to determine the probability of adverse event in pre‐eclampsia patient. Results: Of the 1094 cases of pre‐eclampsia identified, 202 (18.46%) developed adverse outcomes. The majority of adverse consequences were cardiorespiratory complications (110 cases, 54.46%), intensive care unit admissions (66 cases, 32.67%), and hematologic disorders (50 cases, 24.75%). Maternal death occurred in four cases (0.37%). Significant risk factors included a history of drug abuse, dyspnea, visual disturbance, systolic blood pressure ≥180 mmHg, hemoglobin 35 IU/L, lactate dehydrogenase >500 IU/L, INR >1, creatinine >1 mg/dL, urine protein/creatinine ratio >1 mg/mg, and uric acid >7.5 mg/dL. The regression model for prediction of adverse maternal outcomes in pre‐eclampsia achieved a receiver operating characteristic area of 0.86 (95% confidence interval: 0.83–0.89). Pre‐eclampsia patients with a total score of ≥3 had an increased risk of developing adverse maternal outcomes (sensitivity: 80%, specificity: 78%). Conclusion: A new simplified scoring model and nomogram based on clinical characteristics and laboratory tests were developed to facilitate risk stratification of adverse maternal outcomes associated with pre‐eclampsia in routine clinical practice.


  • Successful multidisciplinary team management of placenta accreta spectrum disorder: A referral center model in a middle‐income country

    by Kan Muadtongon, Athithan Rattanaburi, Thiti Ajimakul, Yuthasak Suphasynth, Ingporn Jiamset, Kulisara Nantamongkolkul, Thitima Suntharasaj, Chitkasaem Suwanrath, Ninlapa Pruksanusak, Chusana Petpichetchian, et al.

    Objective: The aim of the study was to evaluate the outcomes of placenta accreta spectrum (PAS) disorder managed by a multidisciplinary care team (MCT) compared with a conventional care team (CCT) in a PAS referral center in Thailand.Methods: This retrospective single‐center cohort study analyzed PAS management outcomes in the PSU PAS Center between January 2010 and December 2022. The incidence of hemorrhage ≥3500 mL and the composite maternal and neonatal outcomes of PAS were compared before and after the introduction of an MCT in 2016.Results: Of 227 PAS cases, 219 (96.5%) had pathological confirmation. There were 52 (22.9%) cases of placenta accreta, 119 (52.4%) cases of placenta increta, and 56 (24.7%) cases of placenta percreta. The incidence of estimated blood loss (EBL) ≥3500 mL decreased from 61.8% to 34.3% (P < 0.001) after the establishment of the MCT. The median EBL decreased from 4000 (IQR: 2600,7250) mL to 2250 (1300, 4750) mL (P < 0.001). EBL reduction was statistically significant in the accreta and increta groups (P < 0.001). Red blood cell transfusions decreased from five (3, 9) to two (1, 6) units (P < 0.001) per patient. The length of maternal hospital stays and ICU admissions were statistically shorter when PAS was managed by an MCT (P < 0.001). The length of newborn hospital and ICU stays decreased significantly (P < 0.001).Conclusion: The incidence of massive postpartum hemorrhage and a composite of maternal and neonatal morbidities in pregnant women with PAS disorder improved significantly after the establishment of an MCT to manage PAS in a middle‐income country setting.


  • Open Access

    Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma

    by Nardhy Gomez-Lopez, Roberto Romero, María Fernanda Escobar, Javier Andres Carvajal, Maria Paula Echavarria, Ludwig L. Albornoz, Daniela Nasner, Derek Miller, Dahiana M. Gallo, Jose Galaz, et al.

    Background: Pregnant women are at greater risk of adverse outcomes, including mortality, as well as obstetrical complications resulting from COVID-19. However, pregnancy-specific changes that underlie such worsened outcomes remain unclear.Methods: Plasma samples were collected from pregnant women and non-pregnant individuals (male and female) with (n = 72 pregnant, 52 non-pregnant) and without (n = 29 pregnant, 41 non-pregnant) COVID-19. COVID-19 patients were grouped as asymptomatic, mild, moderate, severe, or critically ill according to NIH classifications. Proteomic profiling of 7,288 analytes corresponding to 6,596 unique protein targets was performed using the SOMAmer platform.Results: Herein, we profile the plasma proteome of pregnant and non-pregnant COVID-19 patients and controls and show alterations that display a dose-response relationship with disease severity; yet, such proteomic perturbations are dampened during pregnancy. In both pregnant and non-pregnant state, the proteome response induced by COVID-19 shows enrichment of mediators implicated in cytokine storm, endothelial dysfunction, and angiogenesis. Shared and pregnancy-specific proteomic changes are identified: pregnant women display a tailored response that may protect the conceptus from heightened inflammation, while non-pregnant individuals display a stronger response to repel infection. Furthermore, the plasma proteome can accurately identify COVID-19 patients, even when asymptomatic or with mild symptoms.Conclusion: This study represents the most comprehensive characterization of the plasma proteome of pregnant and non-pregnant COVID-19 patients. Our findings emphasize the distinct immune modulation between the non-pregnant and pregnant states, providing insight into the pathogenesis of COVID-19 as well as a potential explanation for the more severe outcomes observed in pregnant women.


  • Open Access

    The Vaginal Microbiota in Early Pregnancy Identifies a Subset of Women at Risk for Early Preterm Prelabor Rupture of Membranes and Preterm Birth

    by Roberto Romero, Adi Tarca, Nardhy Gomez-Lopez, Andrew Winters, Jonathan Panzer, Huang Lin, Dereje Gudicha, Jose Galaz, Marcelo Farias-Jofre, David Kracht, et al.

    Spontaneous preterm birth (sPTB) can occur when vaginal bacteria gain access to the amniotic cavity. Thus, the predictive value of the vaginal microbiota for sPTB has been investigated, yet results have been inconclusive. Here, we report the largest study of the vaginal microbiota using longitudinal sampling of 257 cases and 514 controls (2,976 samples). Associations between the microbiota and sPTB were limited to cases of early (delivery <34 weeks) preterm prelabor rupture of membranes (PPROM). Starting with early gestation, microbial diversity was higher in early PPROM cases than controls, as were the relative abundances of Anaerococcus, Mobiluncus, Prevotella, and Sneathia. Random forest models based on data collected before 28 weeks predicted early PPROM [AUC=0.62(0.51−0.73)], while data collected by 24 weeks predicted PPROM with delivery <30 weeks [AUC=0.68(0.53-0.84)]. Therefore, monitoring of the vaginal microbiota profile may have clinical utility to identify a subset of women who will deliver a preterm neonate.


  • Open Access

    Pregnancy-specific responses to COVID-19 are revealed by high-throughput proteomics of human plasma

    by Nardhy Gomez-Lopez, Roberto Romero, Maria Escobar, Javier Carvajal, Maria Echavarria, Ludwig Albornoz, Daniela Nasner, Derek Miller, Dahiana Gallo, Jose Galaz, et al.

    Pregnant women are at greater risk of adverse outcomes, including mortality, as well as obstetrical complications resulting from COVID-19. However, pregnancy-specific changes that underlie such worsened outcomes remain unclear. Herein, we profiled the plasma proteome of pregnant and non-pregnant COVID-19 patients and controls and showed alterations that display a dose-response relationship with disease severity; yet, such proteomic perturbations are dampened during pregnancy. In both pregnant and non-pregnant state, the proteome response induced by COVID-19 showed enrichment of mediators implicated in cytokine storm, endothelial dysfunction, and angiogenesis. Shared and pregnancy-specific proteomic changes were identified: pregnant women display a tailored response that may protect the conceptus from heightened inflammation, while non-pregnant individuals display a stronger response to repel infection. Furthermore, the plasma proteome can accurately identify COVID-19 patients, even when asymptomatic or with mild symptoms. This study represents the most comprehensive characterization of the plasma proteome of pregnant and non-pregnant COVID-19 patients.


  • Low‐dose aspirin for prevention of preeclampsia: Implementation of the NICE guideline in Thailand

    by Manaphat Suksai, Alan Geater, Thitima Suntharasaj, Chitkasaem Suwanrath, Kla Charernjiratragul, Noppasin Khwankaew

    Aim: To evaluate the effectiveness of a preeclampsia (PE) screening program using the National Institute for Health and Care Excellence (NICE) guideline in pregnant Thai women.Methods: A total of 2552 pregnancies received antenatal care and were delivered at Songklanagarind Hospital between November 2016 and April 2020. PE screening with the NICE guideline was used to identify mothers at risk. In cases of positive screening results, a daily dose of 81 mg aspirin was prescribed. Pregnancy outcomes were compared with 2783 participants who had maternity care before the implementation of the screening program. The effectiveness of aspirin prophylaxis following the NICE guideline was assessed by a logistic regression model to compare the risk of PE development between before and after guidance.Results: The screening positive rate by NICE was 8.3%. Of these, 77.36% of the participants received aspirin prophylaxis according to the NICE recommendation. After the implementation of the PE screening program, the incidence of PE slightly decreased (from 4.31% to 3.72%, p = 0.274). The chance of PE in pregnancies who had high‐risk factors was reduced after using low‐dose aspirin prophylaxis, even though the difference was not statistically significant.Conclusions: Screening with the NICE guidelines followed by prescription of low‐dose aspirin (81 mg/day) was probably not an effective strategy for the prevention of PE in our population. Combining biophysical and biochemical markers to identify pregnant women who subsequently develop PE, concurrently with an increased dose of aspirin prophylaxis, may provide a better outcome in clinical practice.


  • Relationship of anthropometric measurements with glycated hemoglobin and 1‐h blood glucose after 50 g glucose challenge test in pregnant women: A longitudinal cohort study in Southern Thailand

    by Tippawan Liabsuetrakul, Wilaiwan Sriwimol, Kasemsak Jandee, Manaphat Suksai, Jaeuddress Dyereg

    Aims To assess correlations of anthropometric measurements with glycated hemoglobin (HbA1c) and 1-h blood glucose after a 50 g glucose challenge test during the first and late second trimesters and explore their relationships of anthropometric measurements with neonatal birth weight. Methods A longitudinal study was conducted among pregnant Thai women with gestational age <= 14 weeks. Anthropometric measurements, using body mass index, body compositions, and circumferences, and skinfold thickness, were measured at four-time points: <= 14, 18-22, 24-28, and 30-34 weeks of gestation. HbA1c and 1-h blood glucose were examined at <= 14 and 24-28 weeks. Neonatal birth weight was recorded. Results Of 312 women, HbA1c was more correlated with anthropometric measurements during pregnancy than 1-h blood glucose. At 24-28 weeks, women with high/very high body fat percentage were more likely to have higher HbA1c. Women with high subscapular skinfold thickness were more likely to have higher 1-h blood glucose at <= 14 and 24-28 weeks. High hip circumference significantly increased neonatal birth weights. Conclusion Anthropometric measurements were longitudinally correlated with HbA1c and 1-h blood glucose, higher in the late second than first trimesters, as well as neonatal birth weight. The mechanisms to explain the relationship of different anthropometric measurements are required to be further studied.